Barclays Appoints Khaled Habayeb as a Managing Director in Healthcare Equity Capital Markets
April 08 2020 - 11:30AM
Business Wire
Barclays announces the appointment of Khaled Habayeb as a
Managing Director in Healthcare Equity Capital Markets (ECM). Mr.
Habayeb will be based in New York, and will report to Taylor Wright
and Kristin DeClark, Co-Heads of ECM Americas at Barclays. He will
partner with Joe Lombardo in leading the further development and
execution of the firm’s Healthcare ECM business strategy.
Mr. Habayeb joins Barclays with over seventeen years of
experience in banking, most recently as a Managing Director in the
Global Healthcare Group at Deutsche Bank, where he led
biotechnology sector coverage across therapeutic areas and genomics
subsectors. Prior to joining Deutsche Bank in late 2018, Mr.
Habayeb was a Managing Director and Head of Healthcare ECM at UBS.
In this role he led the origination and execution of public and
private equity transactions for healthcare clients, including in
the biotechnology, tools & diagnostics, medical technology,
healthcare services and information technology subsectors. Before
joining UBS in February 2015, Mr. Habayeb was Head of Investor
Relations at Foundation Medicine, Inc. Mr. Habayeb started his
career at J.P. Morgan, where he worked for over ten years in senior
roles within the Healthcare Equity Capital Markets team.
“Khaled is an outstanding addition to our ECM team and brings
with him a wealth of Healthcare specific knowledge,” said Taylor
Wright, Co-Head of ECM Americas. “His long-established industry
relationships and his extensive transactional experience will
generate great value for our clients.”
“As the Healthcare sector continues to evolve at a rapid pace,
our clients more than ever depend on Barclays for sound strategic
advice and seamless execution,” added Rick Landgarten, Global Head
of Healthcare & Real Estate Groups. “Khaled will help ensure
that we further build on our business strengths and momentum, as we
continue to drive ECM mind and market share with our clients.”
Barclays was ranked number 4 overall in US Healthcare Banking
for 2019 with 6.4% market share, according to Dealogic. Within
this, Barclays was ranked number 1 for US Healthcare High Yield
Bonds, with 19.6% market share, and number 3 for US Healthcare
Corporate Investment Grade Bonds, with 10.6% market share. Also for
2019, Barclays was ranked number 6 overall for US ECM. Year to date
2020, Barclays is ranked number 5 in US Healthcare IPOs, and has
been an active bookrunner on transactions for PPD, Inc. and Beam
Therapeutics.
Barclays is a British universal bank. We are diversified by
business, by different types of customer and client, and geography.
Our businesses include consumer banking and payments operations
around the world, as well as a top-tier, full service, global
corporate and investment bank, all of which are supported by our
service company which provides technology, operations and
functional services across the Group.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200408005521/en/
Andrew Smith +1 212 412 7521 andrew.x.smith@barclays.com
Barclays (NYSE:BCS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Barclays (NYSE:BCS)
Historical Stock Chart
From Mar 2023 to Mar 2024